Preoperatiye interleukin-2 immunotherapy in pancreatic cancer: Preliminary results

Carlo Angelini, Giorgio Bovo, Pietro Muselli, Chiara Mussi, Stefano Crippa, Roberto Caprotti, Franco Uggeri

Research output: Contribution to journalArticlepeer-review


Background/Aims: Cancer patients' immunodeficiency, made worse by surgery, represents a poor prognostic factor for postoperative complications and long-term survival. Interleukin-2 has been shown to contrast the immunodeficiency related to the tumor and surgical treatment. The aim of this study is to evaluate the effectiveness of preoperative immunotherapy with interleukin-2 in pancreatic cancer patients. Methodology: 19 patients with pancreatic cancer undergoing radical surgery were divided in 2 different groups. Group 1: 9 patients treated with preoperative Interleukin-2 (9 million IU of IL-2 s.c. for 3 consecutive days) followed by pancreaticoduodenectomy after 36 hours; group 2:10 patients who underwent pancreaticoduodenectomy without any neoadjuvant treatment. Two groups were well matched for age, sex, stage of disease, preoperative tumor markers and preoperative hematological assessment. Inflammatory cells' infiltration on the resected specimens, pre- and postoperative blood lymphocyte counts were evaluated as well as postoperative complications and survival and compared between the groups. Results: Hematological and histological findings showed no significant difference between the 2 groups. Postoperative complications were more frequent in the control than in the treated group (p

Original languageEnglish
Pages (from-to)141-144
Number of pages4
Issue number67
Publication statusPublished - Jan 2006


  • Cancer
  • Immunodeficiency
  • Immunotherapy
  • Interleukin-2
  • Lymphocytopenia
  • Pancreatic cancer

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Preoperatiye interleukin-2 immunotherapy in pancreatic cancer: Preliminary results'. Together they form a unique fingerprint.

Cite this